Newron Pharmaceuticals S.p.A. (NWPHF)
OTCMKTS · Delayed Price · Currency is USD
12.00
+0.60 (5.26%)
May 15, 2024, 8:30 AM EST
Newron Pharmaceuticals Revenue
Newron Pharmaceuticals had revenue of 11.90M EUR in the half year ending June 30, 2025, with 116.56% growth. This brings the company's revenue in the last twelve months to 59.88M, up 759.12% year-over-year. In the year 2024, Newron Pharmaceuticals had annual revenue of 51.39M with 467.41% growth.
Revenue (ttm)
59.88M EUR
Revenue Growth
+759.12%
P/S Ratio
7.21
Revenue / Employee
2.72M EUR
Employees
22
Market Cap
506.96M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.39M | 42.33M | 467.41% |
| Dec 31, 2023 | 9.06M | 2.96M | 48.62% |
| Dec 31, 2022 | 6.09M | 332.00K | 5.76% |
| Dec 31, 2021 | 5.76M | 504.00K | 9.59% |
| Dec 31, 2020 | 5.26M | -1.78M | -25.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Newron Pharmaceuticals News
- 9 days ago - Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia - Business Wire
- 5 weeks ago - EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - Business Wire
- 5 weeks ago - Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent - Business Wire
- 7 weeks ago - Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week - Business Wire
- 2 months ago - Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS) - Business Wire
- 4 months ago - Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025 - Business Wire
- 5 months ago - Newron presents H1 2025 results and provides business update - Business Wire
- 5 months ago - Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP) - Business Wire